Form 8-K - Current report:
SEC Accession No. 0001641172-25-014318
Filing Date
2025-06-09
Accepted
2025-06-09 16:30:22
Documents
12
Period of Report
2025-06-09
Items
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 39432
  Complete submission text file 0001641172-25-014318.txt   205900

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE erna-20250609.xsd EX-101.SCH 3014
3 XBRL LABEL FILE erna-20250609_lab.xml EX-101.LAB 34239
4 XBRL PRESENTATION FILE erna-20250609_pre.xml EX-101.PRE 22358
14 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3698
Mailing Address 10531 4S COMMONS DRIVE SUITE 166-550 SAN DIEGO CA 92127
Business Address 1035 CAMBRIDGE STREET SUITE 18A CAMBRIDGE MA 02141 (617) 798-6700
Ernexa Therapeutics Inc. (Filer) CIK: 0000748592 (see all company filings)

EIN.: 311103425 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-11460 | Film No.: 251034510
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)